Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.

doi:10.21873/anticanres.18361

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.

Anticancer research - 1 Sept 2026

Endo Masashi, Fukuda Yukiko, Nakagawa Machi, Ogawa Kazunari, Nakamura Michiko, Irie Daisuke, Takahashi Satoru, Kawahara Masahiro, Akahane Keiko, Maemondo Makoto, Yamaguchi Yasuhiro, Mori Harushi, Shirai Katsuyuki

Abstract excerpt

BACKGROUND/AIM: The efficacy of durvalumab consolidation therapy after chemoradiotherapy (PACIFIC regimen) for patients with epidermal growth factor receptor (EGFR) mutation-positive locally advanced unresectable non-small cell lung cancer (NSCLC) remains unclear. Additionally, data on failure patterns, including in-field recurrence (IFR) and out-of-field recurrence (OFR), are limited. PATIENTS AND METHODS: In...

Read the complete abstract on PubMed

Topics

Humans
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Lung Neoplasms

Chemoradiotherapy

Neoplasm Recurrence, Local

Aged

Male

Female

Middle Aged

Retrospective Studies

Consolidation Chemotherapy

Antineoplastic Agents, Immunological

Adult

Source

Open in PubMed

Identifiers

PMID: 42674719
DOI: 10.21873/anticanres.18361

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation.PMID 42674719Read ↗

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.Semantic proximity Read ↗

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.Semantic proximity Read ↗

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Semantic proximity Read ↗

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.Semantic proximity Read ↗

Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisSemantic proximity Read ↗

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.Semantic proximity Read ↗

A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).Semantic proximity Read ↗

Pattern of failure and clinical value of local therapy for oligo-recurrence in locally advanced non-small cell lung cancer after definitive chemoradiation: Impact of driver mutation status.Semantic proximity Read ↗

Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.Semantic proximity Read ↗

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).Semantic proximity Read ↗

Survival outcomes in EGFR-mutant versus wild-type locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy alone in the pre-PACIFIC/LAURA trial era: A systematic review and meta-analysis using reconstructed individual patient data.Semantic proximity Read ↗

Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease and Oligo-Progressive Disease in EGFR-Mutated Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.